UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

July 12, 2022

Date of Report (date of earliest event reported)

 

UpHealth, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware		001-38924		83-3838045
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

14000 S. Military Trail, Suite 203

Delray Beach, FL 33484

(Address of principal executive offices)

(312) 618-1322

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		UPH.BC		New York Stock Exchange
Redeemable Warrants, exercisable for one share of Common Stock at an exercise price of $11.50 per share		UPH.WS.BC		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 8, 2022, Moshe Bar-Siman-Tov submitted a letter of resignation to the Chairman of the Board of Directors (the “Board”) from his position as a Class I director of UpHealth, Inc. (the “Company”). On July 11, 2022, the Board accepted Mr. Bar-Siman-Tov’s resignation, which shall be effective as of July 8, 2022. Mr. Bar-Siman-Tov’s resignation is not as a result of any disagreements with the Company.

Furthermore, on July 11, 2022, the Board appointed Samuel J. Meckey, the Company’s new Chief Executive Officer, to serve as a Class I director. The appointment of Mr. Meckey fills the vacancy created by Mr. Bar-Siman-Tov’s resignation. As a Class I director, Mr. Meckey’s term will expire at the Company’s annual meeting of stockholders in 2022, or until his successor is duly elected and qualified, or until his earlier resignation, removal or death.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 12, 2022